April 18, 2012 04:08 ET

Market Research Forecasts Ophthalmic Pharmaceutical Market Growth at 4.6% CAGR Through 2016

ROCKVILLE, MD--(Marketwire - Apr 18, 2012) - has announced the addition of the new report "The Ophthalmic Pharmaceutical Market Outlook to 2016" to their collection of Therapeutic Area market reports. For more information, visit

The $16.2 billion ophthalmic pharmaceutical market will grow steadily at a CAGR of 4.6% to 2016. Although glaucoma is the largest segment most of the growth will come from retinal diseases such as age-related macular degeneration and diabetic retinopathy.

Glaucoma is the largest segment within the ophthalmic market, with sales of $5.6bn in 2010, which will grow at a CAGR of 2.5% to 2016. Xalatan sales are eroding in the US since its patent expiry in March 2011. If an EU pediatric extension is granted the brand will remain protected until January 2012.

Increased use of contact lenses and computers has led to increase dry eye syndrome (DES) in younger age groups. Despite this artificial tear market is expected to be static to 2016.

The retinal disease segment which includes age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME) and retinal vein occlusion (RVO) was valued at $3.5bn in 2010, and will be the fastest growing area with a CAGR of 14.1% to 2016.

For more information, visit

About is the leading provider of global market intelligence products and services. With research reports from more than 720 top consulting and advisory firms, offers instant online access to the world's most extensive database of expert insights on global industries, companies, products, and trends. Moreover,'s Research Specialists have in-depth knowledge of the publishers and the various types of reports in their respective industries and are ready to provide research assistance. For more information, call Veronica Franco at 240-747-3016 or visit

Contact Information

  • Contact:
    Veronica Franco
    Email Contact